The Renin-Angiotensin System in Parkinson’s Disease
- 1st Edition, Volume 9 - October 1, 2025
- Imprint: Academic Press
- Editors: Santiago Perez Lloret, Peter Jenner, Matilde Otero-Losada, Cristian Falup-Pecurariu
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 4 1 3 3 7 - 7
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 4 1 3 3 8 - 4
The Renin-Angiotensin System in Parkinson’s Disease, Volume Nine in the International Review of Movement Disorders series, highlights new advances in the field, with this new volum… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThe Renin-Angiotensin System in Parkinson’s Disease, Volume Nine in the International Review of Movement Disorders series, highlights new advances in the field, with this new volume presenting interesting chapters on topics such as The Renin-Angiotensin-Aldosterone System (RAAS) in health and disease, An overview and history of RAAS discovery and its significance in cardiovascular physiology, The Renin-Angiotensin-Aldosterone System (RAAS) in the cardiovascular system, Other RAAS endocrine systems, RAAS physiology and pharmacology, Effects of the RAAS on inflammation, RAAS genetics, RAAS local brain systems, The Renin-Angiotensin System in neurodegenerative diseases: general considerations, and much more.
Other chapters cover Renin-Angiotensin System modulation of dopaminergic neurotransmission: effects on Parkinson’s Disease motor symptoms and motor fluctuations, Renin-angiotensin System effects on mood in Parkinson’s Disease and other conditions, Renin-angiotensin System effects on cognition in Parkinson’s Disease and other conditions, The potential neuroprotective effect of the Renin-angiotensin System, The relationship between the Renin-Angiotensin System, COVID-19, and Parkinson’s Disease, and The relationship between RAS and other pathological conditions that increase the risk of PD.
Other chapters cover Renin-Angiotensin System modulation of dopaminergic neurotransmission: effects on Parkinson’s Disease motor symptoms and motor fluctuations, Renin-angiotensin System effects on mood in Parkinson’s Disease and other conditions, Renin-angiotensin System effects on cognition in Parkinson’s Disease and other conditions, The potential neuroprotective effect of the Renin-angiotensin System, The relationship between the Renin-Angiotensin System, COVID-19, and Parkinson’s Disease, and The relationship between RAS and other pathological conditions that increase the risk of PD.
- Provides the latest information on the Renin-Angiotensin System in Parkinson’s Disease research
- Offers outstanding and original reviews on a range of the Renin-Angiotensin System in Parkinson’s Disease research topics
- Serves as an indispensable reference for researchers and students alike
Undergraduates, graduates, academics, and researchers
I. The Renin-Angiotensin-Aldosterone System (RAAS) in health and disease
1. An overview and history of RAAS discovery and its significance in cardiovascular physiology
2. The Renin-Angiotensin-Aldosterone System (RAAS) in the cardiovascular system
Marcelo R. Choi Sr.
3. Other RAAS endocrine systems
4. RAAS physiology and pharmacology
5. Effects of the RAAS on inflammation.
6. RAAS genetics
7. RAAS local brain systems
II. 'The Renin-Angiotensin System in Parkinson’s disease
8. The Renin-Angiotensin System in neurodegenerative diseases: general considerations
9. Renin-Angiotensin System modulation of dopaminergic neurotransmission: effects on Parkinson’s Disease motor symptoms and motor fluctuations.
Francisco Capani
10. Renin-angiotensin System effects on mood in Parkinson’s Disease and other conditions.
Santiago Perez-Lloret
11. Renin-angiotensin System effects on cognition in Parkinson’s Disease and other conditions.
12. The potential neuroprotective effect of the Renin-angiotensin System
Santiago Perez-Lloret
13. The relationship between the Renin-Angiotensin System, COVID-19, and Parkinson’s Disease
14. The relationship between RAS and other pathological conditions that increase the risk of PD
1. An overview and history of RAAS discovery and its significance in cardiovascular physiology
2. The Renin-Angiotensin-Aldosterone System (RAAS) in the cardiovascular system
Marcelo R. Choi Sr.
3. Other RAAS endocrine systems
4. RAAS physiology and pharmacology
5. Effects of the RAAS on inflammation.
6. RAAS genetics
7. RAAS local brain systems
II. 'The Renin-Angiotensin System in Parkinson’s disease
8. The Renin-Angiotensin System in neurodegenerative diseases: general considerations
9. Renin-Angiotensin System modulation of dopaminergic neurotransmission: effects on Parkinson’s Disease motor symptoms and motor fluctuations.
Francisco Capani
10. Renin-angiotensin System effects on mood in Parkinson’s Disease and other conditions.
Santiago Perez-Lloret
11. Renin-angiotensin System effects on cognition in Parkinson’s Disease and other conditions.
12. The potential neuroprotective effect of the Renin-angiotensin System
Santiago Perez-Lloret
13. The relationship between the Renin-Angiotensin System, COVID-19, and Parkinson’s Disease
14. The relationship between RAS and other pathological conditions that increase the risk of PD
- Edition: 1
- Volume: 9
- Published: October 1, 2025
- Imprint: Academic Press
- No. of pages: 422
- Language: English
- Hardback ISBN: 9780443413377
- eBook ISBN: 9780443413384
PJ
Peter Jenner
Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson’s disease. He has spent the major part of his career at King’s College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King’s College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.
Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson’s disease patient-carer groups across the UK.
Affiliations and expertise
Emeritus Professor of Pharmacology, Institute of Pharmaceutical Sciences, King’s College London, London, UKMO
Matilde Otero-Losada
Affiliations and expertise
National Research Council (CONICET), CAECIHS.UAI.CONICET, Topic Editor, Neuropharmacology Section, Frontiers in Pharmacology, Buenos Aires, ArgentinaCF
Cristian Falup-Pecurariu
Cristian Falup-Pecurariu is Head of the Department of Neurology, County Clinic Hospital from Brasov, and is Full Professor of Neurology at the Transilvania University from Brasov, Romania. He received his medical degree from the University of Medicine and Pharmacy “Iuliu Hatieganu” from Cluj-Napoca. He hold a 1 year fellowship of the European Neurological Society in movement disorders at Hospital Clinic, University of Barcelona, Spain.
During his career Cristian Falup-Pecurariu was President of the European Association of Young Neurologists and Trainees (EAYNT), EAYNT Liasion Officer with World Federation of Neurological Society, co-representative of Europe on the International Working Group for Young Neurologists and Trainees (World Federation of Neurology). He was also Secretary of the EFNS/MDS-ES Panel on Movement Disorders, member of the Educational Committee of MDS-ES, member of the MDS Leadership Task Force and European Academy of Neurology Scientific Panel Movement Disorders, member of the Teaching Course sub-Committee of the European Academy of Neurology (EAN), currently being member of the Program Committee of EAN. Falup-Pecurariu is former Chair of the Education Committee of the MDS-ES, former member of the Executive Committee of MDS-ES, former member of the International Executive Committee of MDS. He is the initiator and Course Director of the Movement Disorders Teaching Course held in Brasov (12th editions). His research focuses on motor and non-motor aspects of Parkinson’s diseases.
Affiliations and expertise
Chair, Department of Neurology, County Emergency Clinic Hospital, Associate Professor of Neurology, Faculty of Medicine, Transilvania University, Brasov, Romania